🇺🇸 FDA
Patent

US 12201639

Aqueous oral pharmaceutical suspension compositions

granted A61KA61K31/573A61K47/02

Quick answer

US patent 12201639 (Aqueous oral pharmaceutical suspension compositions) held by ReveraGen BioPharma, Inc. expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ReveraGen BioPharma, Inc.
Grant date
Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/573, A61K47/02, A61K47/10, A61K47/12